$100.00 Original price was: $100.00.$70.00Current price is: $70.00.
47 in stock
CAS Number: 118457-14-0
Molecular Formula: C₂₂H₂₅F₂NO₄
Molar Mass: 405.44 g/mol
Purity: ≥99% (HPLC)
Form: Fine crystalline powder
Synonyms: Nebilet™, Bystolic™ (reference standard), (±)-Nebivolol
Nebivolol is a potent and selective β1-adrenergic receptor antagonist with additional vasodilatory properties attributed to its nitric oxide (NO) modulatory effects. Widely researched in cardiovascular science, this compound offers dual-action potential, making it a valuable tool in preclinical and cellular studies related to hypertension, endothelial function, and oxidative stress response.
At CombatResearch.io, our Nebivolol is synthesized to ≥99% purity and is intended strictly for in vitro and analytical research applications. Each batch undergoes rigorous quality control to ensure reliability and reproducibility for professional lab environments.
β1-Adrenergic receptor binding assays
Studies on vascular nitric oxide modulation
Oxidative stress and endothelial function research
Cardiometabolic modeling and signal transduction pathways
Preclinical antihypertensive mechanism exploration
Store at 2–8°C in a dry, well-ventilated area
Protect from light and moisture
Use only in a certified laboratory setting with proper PPE
This product is sold exclusively through CombatResearch.io for laboratory research use only. It is not intended for human or veterinary use and is not approved by the FDA for therapeutic or diagnostic applications. All users must be qualified professionals or institutions familiar with proper handling and local regulations.
Note: Product images and chemical data provided are for informational and educational purposes only.
Only logged in customers who have purchased this product may leave a review.
$165.00 Original price was: $165.00.$129.00Current price is: $129.00.
$35.99 Original price was: $35.99.$27.99Current price is: $27.99.
$75.00 Original price was: $75.00.$60.00Current price is: $60.00.
Reviews
There are no reviews yet.